These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3194 related articles for article (PubMed ID: 25485915)

  • 41. Low-molecular-weight heparin prophylaxis 24 to 36 hours after degenerative spine surgery: risk of hemorrhage and venous thromboembolism.
    Strom RG; Frempong-Boadu AK
    Spine (Phila Pa 1976); 2013 Nov; 38(23):E1498-502. PubMed ID: 23873245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.
    Rothberg MB; Pekow PS; Lahti M; Lindenauer PK
    J Hosp Med; 2012; 7(6):457-63. PubMed ID: 22473716
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Venous thromboembolism: risk factors for recurrence.
    Zhu T; Martinez I; Emmerich J
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):298-310. PubMed ID: 19228602
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.
    Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH
    J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
    Reeves D; Liu CY
    J Oncol Pharm Pract; 2010 Mar; 16(1):27-31. PubMed ID: 19401307
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2011 Jun; (6):CD006649. PubMed ID: 21678360
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006649. PubMed ID: 21328285
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The treatment of venous thromboembolism in patients with cancer.
    Prandoni P
    Intern Emerg Med; 2010 Oct; 5 Suppl 1():S27-30. PubMed ID: 20865471
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk assessment models for cancer-associated venous thromboembolism.
    Dutia M; White RH; Wun T
    Cancer; 2012 Jul; 118(14):3468-76. PubMed ID: 22086826
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.
    Schulman S; Zondag M; Linkins L; Pasca S; Cheung YW; de Sancho M; Gallus A; Lecumberri R; Molnar S; Ageno W; Le Gal G; Falanga A; Hulegårdh E; Ranta S; Kamphuisen P; Debourdeau P; Rigamonti V; Ortel TL; Lee A
    J Thromb Haemost; 2015 Jun; 13(6):1010-8. PubMed ID: 25851122
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Prophylaxis and treatment of thromboembolism in oncology].
    Kessler P
    Vnitr Lek; 2009 Mar; 55(3):219-22. PubMed ID: 19378850
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oral anticoagulant therapy in venous thromboembolism.
    Cosmi B; Palareti G
    Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice.
    Soto-Cárdenas MJ; Pelayo-García G; Rodríguez-Camacho A; Segura-Fernández E; Mogollo-Galván A; Giron-Gonzalez JA
    Palliat Med; 2008 Dec; 22(8):965-8. PubMed ID: 18952751
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predicting recurrent venous thromboembolism in cancer: is it possible?
    Kyrle PA
    Thromb Res; 2014 May; 133 Suppl 2():S17-22. PubMed ID: 24862139
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Venous thromboembolism in cystic fibrosis.
    Takemoto CM
    Pediatr Pulmonol; 2012 Feb; 47(2):105-12. PubMed ID: 22006666
    [TBL] [Abstract][Full Text] [Related]  

  • 56. VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients.
    Cohen AT; Nandini B; Wills JO; Ota S
    Thromb Res; 2010 Apr; 125 Suppl 2():S21-9. PubMed ID: 20434000
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials.
    Thaler J; Ay C; Pabinger I
    Thromb Haemost; 2012 Dec; 108(6):1042-8. PubMed ID: 22836491
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study.
    Kopolovic I; Lee AY; Wu C
    Ann Hematol; 2015 Feb; 94(2):329-36. PubMed ID: 25190031
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical analysis of 20 pregnant women with venous thromboembolic disease].
    Sun P; Dong DN
    Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):911-6. PubMed ID: 22333281
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinux.
    Di Nisio M; Porreca E
    Drug Des Devel Ther; 2013; 7():973-80. PubMed ID: 24068866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 160.